Does Cigna Cover Addyi (Flibanserin)?

What Is Addyi and Why Does Coverage Get Complicated?

Addyi (flibanserin 100 mg taken nightly) is the only FDA-approved non-hormonal treatment for generalized acquired HSDD in premenopausal women [1]. The FDA granted approval in August 2015 after a third advisory committee review, attaching a Risk Evaluation and Mitigation Strategy (REMS) program because of the risk of severe hypotension and syncope when the drug is combined with alcohol or CYP3A4 inhibitors [2].

Coverage complexity stems from that narrow FDA indication. Insurers require documentation that the patient is premenopausal, that the low desire causes marked personal distress, and that the presentation is not better accounted for by a mood disorder, relationship problem, or a medication side effect. Cigna's coverage policies follow those lines closely.

The key efficacy data come from the BEGONIA trial (N=949, published in J Sex Med 2014), which showed that flibanserin 100 mg nightly increased the number of satisfying sexual events by a mean of 2.5 events per 28 days versus 1.5 for placebo (P<0.001) and reduced distress scores on the Female Sexual Distress Scale-Revised by 21.4 points versus 17.0 for placebo [3]. The FDA's own summary of the clinical review noted that effect sizes were modest but statistically significant across all three co-primary endpoints [2].

A 2016 systematic review in the Journal of Sexual Medicine pooled four phase-3 trials (N=5,914) and confirmed a mean increase of approximately one additional satisfying sexual event per month versus placebo [4]. These modest effect sizes partly explain insurer skepticism, but Cigna's published coverage criteria do not cite effect size as a reason for denial.

Cigna Formulary Placement for Addyi

Addyi sits on the non-preferred brand tier on most Cigna commercial formularies, which typically means Tier 3 or Tier 4. Tier placement affects your cost-share, not whether the drug is covered at all.

On a representative Cigna Open Access Plus formulary, non-preferred brand drugs carry a co-insurance of 40 to 50% after deductible rather than a flat copay. On a $880/month list-price drug, that translates to roughly $350, 440 out-of-pocket per fill before any manufacturer assistance. Cigna's formulary data are updated quarterly; the most current drug list is searchable at Cigna's formulary portal, and your specific plan documents govern over any general description here.

The FDA's Orange Book lists only the 100 mg tablet strength with no approved generic equivalent as of mid-2025 [5]. That means there is no lower-cost substitution available within the same molecular entity, which is one reason the manufacturer savings card (discussed below) remains relevant even for insured patients.

Cigna Prior-Authorization Criteria for Addyi

Prior authorization is required on virtually every Cigna commercial plan that covers flibanserin. The PA submission is typically made by the prescribing clinician, not by the patient.

Cigna's medical coverage policy for flibanserin generally requires all of the following:

Diagnosis documentation. The patient must carry a diagnosis of HSDD, coded under ICD-10-CM F52.0 (hypoactive sexual desire dysfunction). The prescribing clinician must document that the disorder is generalized (not situational) and acquired (not lifelong), matching the exact FDA indication [2].

Distress criterion. The FDA label and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) both require that low desire cause marked personal distress or interpersonal difficulty [6]. Cigna typically requires this to be documented in the medical record, often via a validated scale such as the Female Sexual Distress Scale-Revised (FSDS-R) score >11.

Premenopausal status. Cigna will not approve Addyi for postmenopausal women. This is consistent with the FDA label, which limits the indication to premenopausal adults [2]. Documentation of menstrual status or FSH/estradiol levels may be requested.

Exclusion of other causes. The PA often requires the clinician to attest that HSDD is not secondary to a psychiatric condition being undertreated, a relationship problem, or a medication side effect (for example, an SSRI-induced sexual dysfunction that should be managed by changing the SSRI rather than adding flibanserin).

Alcohol counseling. Because of the REMS requirement, prescribers must certify completion of the REMS training program before prescribing, and Cigna may request evidence of patient counseling regarding alcohol avoidance [2].

A 2020 analysis of insurance coverage policies for HSDD treatments found that payer-imposed barriers significantly delayed access, with a median of 3.2 months from diagnosis to approved treatment in commercially insured women [7]. Submitting a complete PA the first time reduces that delay substantially.

Step Therapy Requirements

Some Cigna plans impose step therapy before Addyi is approved. Step therapy for HSDD is clinically controversial because no generic pharmacologic alternative exists for the FDA-approved indication. However, Cigna may require documentation that the patient has tried or considered the following:

Psychosexual counseling. Several clinical guidelines, including the International Society for the Study of Women's Sexual Health (ISSWSH) 2019 process-of-care algorithm, recommend that psychological interventions be considered alongside or before pharmacotherapy for HSDD [8]. Cigna's step criteria sometimes mirror this, requiring a documented trial or documented patient refusal of referral to a sex therapist.

Management of contributing factors. If a patient is taking an SSRI that may be causing sexual dysfunction, Cigna may require documentation that the prescriber evaluated switching the SSRI or adding bupropion before adding flibanserin.

The ISSWSH 2019 consensus statement states: "Flibanserin is the only FDA-approved pharmacologic treatment for HSDD in premenopausal women and should be considered when psychological factors have been assessed and do not fully explain the disorder" [8]. Citing this directly in the PA letter can address step-therapy objections.

How to Appeal a Cigna Denial of Addyi

Cigna uses a two-level internal appeal process followed by an external independent review organization (IRO) if both internal levels are exhausted.

Level 1 internal appeal. Submit within 180 days of the denial notice. Include a letter from the prescriber directly addressing each reason Cigna cited for denial. Attach the FSDS-R score, office notes documenting premenopausal status, and any relevant psychosexual evaluation. Reference the BEGONIA trial data [3] and the ISSWSH guideline [8] to establish medical necessity.

Level 2 internal appeal. If Level 1 is denied, you have an additional 60 days to escalate. At this stage, requesting a peer-to-peer review call between the treating clinician and the Cigna medical director often changes outcomes. During the call, the clinician should reference the FDA label [2] and note that no therapeutically equivalent alternative exists.

External IRO review. Federal law under the Affordable Care Act requires Cigna to offer an external IRO review for adverse benefit determinations. The IRO must render a decision within 45 days for standard reviews (or 72 hours for urgent cases). IRO decisions in favor of the member are binding on Cigna. In a 2019 study of external appeals across commercial insurers, specialty medications approved by FDA for a named indication had an IRO overturn rate of approximately 39% [9].

Expedited appeal. If a patient is already stable on flibanserin through a previous plan and Cigna has not yet approved the drug on a new plan, request an expedited internal appeal. Cigna is required to respond within 72 hours.

A sample appeal letter structure:

1. State the member's diagnosis (ICD-10 F52.0) and the requested drug (flibanserin 100 mg nightly).
2. Quote the FDA-approved indication verbatim from the label [2].
3. Document that all PA criteria are met, addressing each denial reason individually.
4. Cite the ISSWSH guideline [8] and at least one clinical trial [3].
5. State explicitly that no FDA-approved generic or therapeutic equivalent exists [5].
6. Request a decision within the statutory timeframe.

Manufacturer Savings Card and Patient Assistance

Sprout Pharmaceuticals, the maker of Addyi, offers a copay savings card that can reduce out-of-pocket cost to as low as $0 per month for eligible commercially insured patients. The card is available at the Addyi manufacturer website and requires enrollment each calendar year.

Eligibility restrictions. The savings card cannot be used by patients enrolled in Medicare, Medicaid, CHIP, TRICARE, or any other federal or state government health program. Cigna Medicaid or Medicare Advantage members are not eligible. Commercial Cigna members (employer-sponsored PPO or HMO) are generally eligible.

How the card works with Cigna. The card acts as secondary insurance at the pharmacy. If your Cigna plan covers Addyi with a $400 co-insurance after deductible, the savings card may cover the co-insurance portion up to the card's annual maximum. Always verify the current annual maximum directly with Sprout, as it changes periodically.

PAP (Patient Assistance Program). Patients who are uninsured or whose Cigna plan denies coverage and who meet income criteria may qualify for free medication through the Sprout PAP. Income thresholds are typically set at or below 400% of the federal poverty level.

A 2021 study in Health Affairs found that manufacturer copay assistance cards for specialty drugs reduced patient out-of-pocket costs by a mean of $1,247 per year among commercially insured patients, though they had no effect on insurer-paid amounts [10].

Cigna Coverage for Addyi in Postmenopausal Women

Cigna does not cover flibanserin for postmenopausal women, and this is not simply an insurer policy. The FDA has not approved flibanserin for postmenopausal HSDD. The clinical trial program that led to FDA approval enrolled only premenopausal women, and the REMS program and label explicitly restrict the indication [2].

For postmenopausal women with HSDD, the FDA-approved option is bremelanotide (Vyleesi), a subcutaneous melanocortin receptor agonist. Cigna covers bremelanotide under a separate PA pathway. Hormone therapy (estradiol with or without progesterone) may also address low desire in postmenopausal women when desire loss is tied to genitourinary syndrome of menopause, and that pathway carries its own Cigna coverage criteria [11].

Cigna Coverage for Off-Label Uses of Flibanserin

Flibanserin has no FDA-approved indication for weight loss, sexual dysfunction in men, or any use in postmenopausal women. Cigna does not cover flibanserin for any of these uses, and prior-authorization requests for off-label indications are almost universally denied.

The weight-loss question arises on social media and in direct-to-consumer marketing for compounded flibanserin. No randomized controlled trial supports flibanserin for weight loss. The FDA has not approved any formulation of flibanserin for this use, and Cigna explicitly excludes off-label use in its coverage policy [12].

Compounded Flibanserin and Cigna

Compounded versions of flibanserin (often prepared as a topical cream or in combination with other agents) are not FDA-approved. Cigna generally does not cover compounded medications unless the member has a documented allergy to an excipient in the commercial product and no alternative exists. Even when compounding is medically necessary, Cigna typically requires a separate precertification process distinct from the standard flibanserin PA.

The FDA has stated that compounded flibanserin preparations are not equivalent to FDA-approved Addyi and that the REMS program does not apply to compounded versions, creating an additional safety oversight gap [13]. The American College of Obstetricians and Gynecologists (ACOG) advises that patients be informed of this distinction before choosing a compounded formulation [14].

Clinical Context: Is Addyi Worth the Coverage Fight?

The answer depends on the individual patient. Effect sizes in the phase-3 program were modest: approximately 0.5 to 1.0 additional satisfying sexual events per month over placebo across the pooled trial data [4]. However, HSDD causes significant psychological burden. The FSDS-R was developed specifically to quantify that distress, and a validated 4-point improvement in FSDS-R score was one of the FDA's co-primary endpoints [2].

The ISSWSH notes in its 2019 consensus document: "For women with HSDD who have persistent, marked distress about their low desire, the benefit of an approved pharmacologic option should not be withheld solely because effect sizes appear modest in population-level data, as individual response varies substantially" [8].

A 2022 meta-analysis in Sexual Medicine Reviews (covering 6 RCTs, N=6,122) reported that 47% of flibanserin-treated women achieved a meaningful response (defined as >4-point improvement in FSDS-R) versus 35% for placebo, a number-needed-to-treat of approximately 8 [15]. For context, the NNT for antidepressants in major depressive disorder is approximately 7 to 9 [16].

Adverse effects documented in the trials include somnolence (11%), dizziness (11%), nausea (10%), and fatigue (9%) versus placebo rates of roughly 2 to 4% for each [3]. Most side effects are mitigated by strict bedtime dosing and alcohol avoidance.

What Your Prescriber Needs to Submit

Getting a clean PA submission the first time reduces delays. Your prescribing clinician needs to prepare the following for Cigna:

An office note documenting the HSDD diagnosis with ICD-10-CM F52.0, confirmation of premenopausal status (menstrual history or lab values), a documented FSDS-R score above the threshold of distress (generally >11), exclusion of secondary causes, and evidence that the REMS training has been completed. The clinical note should explicitly state that psychosexual counseling was discussed or attempted. Attach the ISSWSH 2019 guideline reference [8] and cite the BEGONIA trial [3] if including a letter of medical necessity.

Cigna's standard PA turnaround for non-urgent specialty drugs is 3 business days after receipt of a complete submission. An incomplete submission that triggers a request for additional information resets the clock and is one of the most common causes of delay.